Intellia rallies on Phase 1 data for CRISPR-based HAE therapy

Like
1
Favorite

Intellia rallies on Phase 1 data for CRISPR-based HAE therapy

seekingalpha06-03

Intellia Therapeutics (NASDAQ:NTLA) stock jumped 13% Monday in the wake of positive long-term data from a Phase 1 study of its CRISPR-based gene therapy NTLA-2002 in the treatment of hereditary ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（1）

True North 8
·06-04
L
Reply
Like
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2440449733?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1794939629/image_1794939629.jpg","is_english":true,"pubTime":"2024-06-03 22:32","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2440449733","market":"hk","top_or_hot":-1,"title":"Intellia rallies on Phase 1 data for CRISPR-based HAE therapy","media":"seekingalpha","content":"<div>\n<p>Intellia Therapeutics (NASDAQ:NTLA) stock jumped 13% Monday in the wake of positive long-term data from a Phase 1 study of its CRISPR-based gene therapy NTLA-2002 in the treatment of hereditary ...</p>\n\n<a href=\"https://seekingalpha.com/news/4112351-intellia-rallies-on-phase-1-data-for-crispr-based-hae-therapy\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intellia rallies on Phase 1 data for CRISPR-based HAE therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntellia rallies on Phase 1 data for CRISPR-based HAE therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-03 22:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4112351-intellia-rallies-on-phase-1-data-for-crispr-based-hae-therapy><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Intellia Therapeutics (NASDAQ:NTLA) stock jumped 13% Monday in the wake of positive long-term data from a Phase 1 study of its CRISPR-based gene therapy NTLA-2002 in the treatment of hereditary ...</p>\n\n<a href=\"https://seekingalpha.com/news/4112351-intellia-rallies-on-phase-1-data-for-crispr-based-hae-therapy\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTLA","symbol_name":"Intellia Therapeutics Inc","start_time":0,"source_url":"https://seekingalpha.com/news/4112351-intellia-rallies-on-phase-1-data-for-crispr-based-hae-therapy","article_id":"2440449733","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1794939629/image_1794939629.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2440449733","pubTimestamp":1717425120,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Intellia Therapeutics  stock jumped 13% Monday in the wake of positive long-term data from a Phase 1 study of its CRISPR-based gene therapy NTLA-2002 in the treatment of hereditary angioedema, or HAE. The biotech company said in a statement that a single dose of NTLA-2002 led to a 98% mean reduction in the monthly attack rate, with an average follow-up of over 20 months across all patients. It added that eight out of ten patients were completely attack-free following a 16-week primary observation period through the last follow-up, including patients with the most severe disease. Intellia presented the data over the weekend at the European Academy of Allergy and Clinical Immunology Congress 2024 meeting in Spain. The company expects to report topline Phase 2 results for the therapy mid-year. A pivotal Phase 3 study is expected to start in the second half of 2024, subject to regulatory feedback.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NTLA":"Intellia Therapeutics Inc","HAE":"美国血液技术","CRSP":"CRISPR Therapeutics AG","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4535":"淡马锡持仓","BK4556":"基因编辑","BK4585":"ETF&股票定投概念","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","BK4198":"医疗保健用品","BK4139":"生物科技","BK4588":"碎股","LU1861558580.USD":"日兴方舟颠覆性创新基金B"},"translate_title":"Intellia因基于CRISPR的HAE疗法1期数据而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRSP":1,"HAE":1,"NTLA":1},"content_text":"Intellia Therapeutics (NASDAQ:NTLA) stock jumped 13% Monday in the wake of positive long-term data from a Phase 1 study of its CRISPR-based gene therapy NTLA-2002 in the treatment of hereditary angioedema, or HAE. The biotech company said in a statement that a single dose of NTLA-2002 led to a 98% mean reduction in the monthly attack rate, with an average follow-up of over 20 months across all patients. It added that eight out of ten patients were completely attack-free following a 16-week primary observation period through the last follow-up, including patients with the most severe disease. Intellia presented the data over the weekend at the European Academy of Allergy and Clinical Immunology Congress 2024 meeting in Spain. The company expects to report topline Phase 2 results for the therapy mid-year. A pivotal Phase 3 study is expected to start in the second half of 2024, subject to regulatory feedback.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":313051700596840,"gmtCreate":1717450954159,"gmtModify":1717451517045,"author":{"id":"4109717836440300","authorId":"4109717836440300","name":"True North 8","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4109717836440300","authorIdStr":"4109717836440300"},"htmlText":"&nbsp;L","listText":"&nbsp;L","text":"L","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/313051700596840","repostId":2440449733,"repostType":2,"repost":{"id":"2440449733","kind":"highlight","pubTimestamp":1717425120,"share":"https://ttm.financial/m/news/2440449733?lang=&edition=fundamental","pubTime":"2024-06-03 22:32","market":"hk","language":"en","title":"Intellia rallies on Phase 1 data for CRISPR-based HAE therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2440449733","media":"seekingalpha","summary":"Intellia Therapeutics  stock jumped 13% Monday in the wake of positive long-term data from a Phase 1 study of its CRISPR-based gene therapy NTLA-2002 in the treatment of hereditary angioedema, or HAE. The biotech company said in a statement that a single dose of NTLA-2002 led to a 98% mean reduction in the monthly attack rate, with an average follow-up of over 20 months across all patients. It added that eight out of ten patients were completely attack-free following a 16-week primary observation period through the last follow-up, including patients with the most severe disease. Intellia presented the data over the weekend at the European Academy of Allergy and Clinical Immunology Congress 2024 meeting in Spain. The company expects to report topline Phase 2 results for the therapy mid-year. A pivotal Phase 3 study is expected to start in the second half of 2024, subject to regulatory feedback.","content":"<html><body><p>Intellia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (<span>NASDAQ:NTLA</span>) stock jumped 13% Monday in the wake of positive long-term data from a Phase 1 study of its CRISPR-based gene therapy NTLA-2002 in the treatment of hereditary angioedema, or HAE.</p> <p>The biotech company said in a statement<span> that a single dose of NTLA-2002 led to a 98% mean reduction in the monthly attack rate, with an average follow-up of over 20 months across all patients. It added that eight out of ten patients were completely attack-free following a 16-week primary observation period through the last follow-up, including patients with the most severe disease.</span></p> <p>Intellia presented the data over the weekend at the European Academy of Allergy and Clinical Immunology Congress 2024 meeting in Spain.</p> <p>The company expects to report topline Phase 2 results for the therapy mid-year. A pivotal Phase 3 study is expected to start in the second half of 2024, subject to regulatory feedback.</p> </body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intellia rallies on Phase 1 data for CRISPR-based HAE therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntellia rallies on Phase 1 data for CRISPR-based HAE therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-03 22:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4112351-intellia-rallies-on-phase-1-data-for-crispr-based-hae-therapy><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Intellia Therapeutics (NASDAQ:NTLA) stock jumped 13% Monday in the wake of positive long-term data from a Phase 1 study of its CRISPR-based gene therapy NTLA-2002 in the treatment of hereditary ...</p>\n\n<a href=\"https://seekingalpha.com/news/4112351-intellia-rallies-on-phase-1-data-for-crispr-based-hae-therapy\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1794939629/image_1794939629.jpg","relate_stocks":{"NTLA":"Intellia Therapeutics Inc","HAE":"美国血液技术","CRSP":"CRISPR Therapeutics AG","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4535":"淡马锡持仓","BK4556":"基因编辑","BK4585":"ETF&股票定投概念","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","BK4198":"医疗保健用品","BK4139":"生物科技","BK4588":"碎股","LU1861558580.USD":"日兴方舟颠覆性创新基金B"},"source_url":"https://seekingalpha.com/news/4112351-intellia-rallies-on-phase-1-data-for-crispr-based-hae-therapy","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2440449733","content_text":"Intellia Therapeutics (NASDAQ:NTLA) stock jumped 13% Monday in the wake of positive long-term data from a Phase 1 study of its CRISPR-based gene therapy NTLA-2002 in the treatment of hereditary angioedema, or HAE. The biotech company said in a statement that a single dose of NTLA-2002 led to a 98% mean reduction in the monthly attack rate, with an average follow-up of over 20 months across all patients. It added that eight out of ten patients were completely attack-free following a 16-week primary observation period through the last follow-up, including patients with the most severe disease. Intellia presented the data over the weekend at the European Academy of Allergy and Clinical Immunology Congress 2024 meeting in Spain. The company expects to report topline Phase 2 results for the therapy mid-year. A pivotal Phase 3 study is expected to start in the second half of 2024, subject to regulatory feedback.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}